Drug Trial Radar · NCT04905693
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,850
Planned (sponsor's estimate)
Start
Sep 6, 2022
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Progressive Pulmonary Fibrosis
Interventions
Inhaled TreprostinilDrug
Inhaled Treprostinil (6 mcg/breath) administered QID
Treprostinil Ultrasonic NebulizerDevice
Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety and tolerability of inhaled treprostinil in subjects with IPF or PPFTime frame: Baseline to 6 years
Locations
192 sites in 18 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Clinical Trials Center of Middle Tennessee
Franklin, Arizona
Banner University Medical Center-Phoenix
Phoenix, Arizona
St. Joseph's Hospital and Medical Center - Norton Thoracic Institute
Phoenix, Arizona
University of Arizona
Tucson, Arizona
UC San Diego Health
La Jolla, California
David Geffen School of Medicine at UCLA
Los Angeles, California
NewportNativeMD, Inc
Newport Beach, California
UC Davis Health Medical Center
Sacramento, California
University of California San Francisco
San Francisco, California
Stanford University School of Medicine
Stanford, California
National Jewish Health
Denver, Colorado
University of Florida Health at Shands
Gainesville, Florida
Ascension St. Vincent's
Jacksonville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Pulmonary Disease Specialists, PA d/b/a PDS Research
Kissimmee, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
University of South Florida Health
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Piedmont Healthcare Atlanta
Atlanta, Georgia
Emory University
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Norton Pulmonary Specialists
Louisville, Kentucky
University of Louisville Healthcare Outpatient Center
Louisville, Kentucky
Tulane University Medical Center
New Orleans, Louisiana
LSU Health Science Center Shreveport
Shreveport, Louisiana
Johns Hopkins Asthma and Allergy Center
Baltimore, Maryland
Adventist Healthcare White Oak Medical Center
Silver Spring, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan Int Med Pulmonary and critical care
Ann Arbor, Michigan
Corewell Health William Beaumont Hospital
Royal Oak, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic, Division of Pulmonary and Critical Care Medicine
Rochester, Minnesota
University Mississippi Medical Center
Jackson, Mississippi
The Lung Research Center, LLC
Chesterfield, Missouri
Washington University School of Medicine
St Louis, Missouri
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.